PharmEasy

What PharmEasy does

PharmEasy is an Indian online health services platform operating under parent company API Holdings Ltd, founded in 2015 and headquartered in Mumbai. It functions as a hybrid marketplace connecting patients, registered retail pharmacies, certified diagnostic labs, and healthcare providers through an integrated stack of consumer-facing and B2B services. The platform serves 51 million+ registered users and has delivered 71 million+ orders across 1,200+ cities and 19,000+ pin codes, claiming approximately 35% market share in India's e-pharmacy segment.

The core platform combines online prescription medicine ordering, an OTC healthcare products catalog of 1 lakh+ SKUs, diagnostic testing powered by Thyrocare (which operates nearly 10,000 franchise locations), teleconsultation services starting from Rs 199, and a PLUS subscription membership. PharmEasy has expanded through approximately 50 acquisitions over the past decade, including Thyrocare (2021) for diagnostics, Aknamed (2021) for hospital supply chain, and Medlife (2020). The B2B distribution arm Ascent now provides 100% internal sourcing for the group, up from 20-30% previously. Distribution has been extended through partnerships with Swiggy Instamart (10-minute prescription delivery pilot in Bengaluru), Samsung Health (Find Care integration launching February 2026), and PhonePe's Pincode quick-commerce platform.

PharmEasy generates revenue through multiple streams: marketplace commissions on medicine sales, 20-25% margins on diagnostic tests (Thyrocare), B2B transaction fees through Ascent, teleconsultation fees, the PLUS subscription (5% extra savings on every order), advertising, and affiliate/referral programs. Private label sub-brands Liveasy and Everherb extend the model into higher-margin owned-brand health products. The company has been backed by Temasek, Naspers, Tiger Global, TPG, and Prosus, with a 2021 peak valuation of $5.6 billion declining to roughly $456-700M by 2024-25. After withdrawing its 2022 IPO, PharmEasy appointed Rahul Guha as MD and CEO in August 2025 and is now executing a profit-first strategy with EBITDA and PAT positivity targeted by March FY27.

Name

PharmEasy

Legal name

PharmEasy

Website

https://pharmeasy.in

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

PharmEasy is India's largest digital healthcare platform, operating a hybrid marketplace for online medicine delivery, diagnostics (via Thyrocare), teleconsultation, and B2B pharmaceutical distribution. Founded in 2015, it serves 51 million+ registered users across 1,200+ cities.

Ownership category

akta.pro rank

Product category

Online Pharmacy & Digital Healthcare

NAICS

Pharmacies and Drug Retailers (456110), Medical and Diagnostic Laboratories (6215)

SIC

Retail-Drug Stores And Proprietary Stores (5912)

akta.pro primary industry

Telepharmacy & Prescription Fulfillment Marketplaces (HLALALAF)

akta.pro secondary industries

DTC Telehealth with Integrated Online Pharmacy (Cash-Pay/Subscription) (HLALAIAA), Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG), Virtual Pharmacy & Medication Management Integration Platforms (HLALABAL)

Keywords

• Online pharmacy services
• Healthcare e-commerce
• Diagnostic testing
• Teleconsultation services
• Medicine delivery platform

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2C

Offering type

Digital Commerce or Content

Cost components

Operations, Marketing or Sales

Revenue model

1. Medicine Commissions: Commission revenue from medicine sales through the platform, operating on marketplace model with registered retail pharmacies
2. Diagnostic Margins: Revenue from diagnostic tests powered by Thyrocare, with margins of 20-25%
3. B2B Distribution: B2B distribution revenue through Ascent, which now provides 100% internal sourcing for the group
4. Doctor Consultations: Revenue from teleconsultation services offered on the platform
5. PLUS Membership: Subscription membership offering 5% extra savings on every order, with complimentary membership offered to Samsung Health users
6. Advertising: Advertising revenue from brands on the platform
7. Loyalty Programs: Revenue from loyalty program offerings and promotional campaigns

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels5 records

Core offering

PharmEasy operates a hybrid digital healthcare marketplace that connects consumers to local pharmacies and certified diagnostic labs for prescription medicine delivery, home-based diagnostic testing, and online doctor consultations. The platform partners with registered retail pharmacies under an asset-light model and supplements this with owned Thyrocare diagnostics and Ascent B2B pharmaceutical distribution, serving over 51 million registered users across 1200+ Indian cities.

Product overview

PharmEasy operates as a hybrid marketplace digital healthcare platform under parent company API Holdings, offering a multi-module ecosystem that connects patients, pharmacies, diagnostic labs, and healthcare providers. The core platform centers on online medicine ordering with prescription upload functionality, supported by integrated add-on modules including healthcare products (OTC), lab tests powered by acquired Thyrocare diagnostics, teleconsultation services, and the PLUS membership subscription program. The company has expanded through acquisitions including Thyrocare (diagnostics) and Aknamed (hospital supply chain), and operates private label sub-brands under Liveasy and PharmEasy for health supplements and medical devices. The platform employs an asset-light model partnering with local pharmacies and certified diagnostic labs, delivering to over 1200 cities across 19000+ pin codes with 51 million registered users.

Differentiator

Problem solved

Functional benefit

Brands

• LiveEasy: PharmEasy's private label brand for health and wellness products including supplements, ortho care items, and healthcare essentials
• Everherb

Quantifiable outcome

• 86% of surveyed users reported visible savings after switching to branded medicine substitutes, with some saving up to 60% on medicine bills
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and major.

• SamsungcoreGTM or Marketing Partner · 19 February 2026Samsung Health partnered with PharmEasy to introduce 'Find Care' feature in Samsung Galaxy devices, launching February 24, 2026. The feature allows users to order medicines, book diagnostic tests, and access online medical consultations directly through the Samsung Health app. PharmEasy offers a complimentary six-month Plus membership to Samsung Health users who complete their first transaction through the app, eliminating the need to switch between multiple healthcare applications.
• AscentcoreStrategic or Co-development Partner · 1 January 2025Ascent is the B2B distribution arm of API Holdings. Internal sourcing from Ascent has increased to 100% vs 20-30% previously as part of the company's turnaround strategy, helping reduce costs and improve operational efficiency.
• Swiggy InstamartcoreChannel Partner/ Reseller/ Distributor · 25 October 2024Swiggy partnered with PharmEasy to pilot 10-minute prescription medicine delivery through its Instamart service in Bengaluru. The partnership allows Swiggy to offer prescription drugs without requiring additional regulatory permissions by leveraging PharmEasy's platform for prescription uploads and doctor consultations. This strategic expansion aims to attract new users, increase average order values, and boost profitability.
• AknamedmajorStrategic or Co-development Partner · 14 September 2021PharmEasy acquired cloud-based hospital supply chain management startup Aknamed in a stock deal worth about $180-190 million. The acquisition is part of PharmEasy's broader strategy to diversify into online healthcare services and was linked to its upcoming IPO.
• ThyrocarecoreStrategic or Co-development Partner · 6 July 2021PharmEasy acquired a majority stake in Thyrocare, one of India's largest diagnostic and preventive healthcare companies founded by Dr. Arokiaswamy Velumani. The acquisition expanded PharmEasy into diagnostic services, with Thyrocare operating franchise model expanding from 2,700 to nearly 10,000 locations. Thyrocare continues to be the profit engine growing at over 20%.
• API HoldingscoreStrategic or Co-development Partner · 1 January 2021PharmEasy operates under parent company API Holdings, India's leading outpatient digital healthcare platform. API Holdings has expanded through nearly 50 acquisitions over the past decade, transitioning into a full-stack healthcare ecosystem focusing on consolidation, digital integration, and AI-driven efficiencies.

Scale indicators12 records

Recent moves7 records

Expansion highlights7 records

Direct peers

• Tata 1mg: Tata-backed e-pharmacy and digital health platform in India offering medicine delivery, diagnostics, and teleconsultation. Direct competitor to PharmEasy with overlapping product suite, target customer base, and asset-light marketplace model.
• Apollo Pharmacy 24/7: Apollo Hospitals' online pharmacy arm offering prescription and OTC medicine delivery plus diagnostic services. Vertically integrated competitor with hospital-backed supply chain competing head-on with PharmEasy across medicine delivery and diagnostics.
• Netmeds: Reliance-owned e-pharmacy platform offering medicine delivery, diagnostics, and teleconsultation across India. Acquired by Reliance Retail, providing deep capital backing and competing directly with PharmEasy in the same e-pharmacy marketplace.
• MedPlus Mart: One of India's largest pharmacy retail chains with an online medicine delivery platform. Combines physical retail footprint with digital ordering, comparable to PharmEasy's hybrid online-offline strategy but with owned retail infrastructure.
• Flipkart Health+: Walmart/Flipkart-owned health platform offering medicine delivery and diagnostics. Leverages Flipkart's massive e-commerce user base and logistics network as direct competition to PharmEasy's online pharmacy and diagnostics offerings.
• Medlife: Indian e-pharmacy platform acquired by PharmEasy in 2020. Pre-acquisition was a direct competitor in online medicine delivery and diagnostics; now folded into PharmEasy's ecosystem but historically comparable as a peer in the same category.

Broad incumbents

• Practo: India's leading doctor consultation and clinic management platform offering teleconsultation, medicine ordering, and diagnostics. Comparable to PharmEasy's teleconsultation and integrated healthcare ecosystem with broader clinical focus beyond pharmacy.
• Amazon Pharmacy: Amazon's online pharmacy offering in India providing prescription and OTC medicine delivery. Leverages Amazon's logistics infrastructure and Prime ecosystem as a broad incumbent with overlapping e-pharmacy offerings.
• Tata Health: Tata Group's broader digital health platform offering teleconsultation, medicine ordering, and health checks. Part of Tata's healthcare conglomerate (Tata 1mg, Tata Medical), comparable as a broad digital health incumbent rather than pure e-pharmacy.

Emerging players

• Zeno Health: India-focused generic medicine retailer and online pharmacy emphasizing affordable branded substitutes. Smaller-scale but directly comparable business model focused on cost-effective medicine delivery, relevant as a niche competitor to PharmEasy's value-oriented positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/pharmeasyapp
• YouTubeyoutube.com/channel/UCDats_DLX-bGZH3-KGu8JhA
• Facebookfacebook.com/pharmeasy
• Instagraminstagram.com/pharmeasyapp
• LinkedInlinkedin.com/company/pharmeasy

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds17 records

Investors47 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmEasy